This clinical trial is focused on studying the effects of a treatment called Astegolimab in patients with Chronic Obstructive Pulmonary Disease (COPD). COPD is a long-term lung disease that makes it hard to breathe. The study aims to evaluate how well Astegolimab works in reducing the number of moderate and severe flare-ups of COPD over a year of treatment. Astegolimab is a type of medication known as a monoclonal antibody, which is a protein designed to target specific substances in the body.

Participants in the study will receive either Astegolimab or a placebo. The study will last for 52 weeks, during which the effects of the treatment on COPD symptoms will be closely monitored. The study will also look at how the treatment affects the quality of life of the participants, using a questionnaire designed to measure respiratory health. Additionally, the study will assess changes in lung function and the occurrence of any side effects.

Throughout the study, participants will continue their usual COPD maintenance therapy, which may include medications like inhaled corticosteroids, long-acting beta2-agonists, and long-acting muscarinic antagonists. The goal is to see if adding Astegolimab to these standard treatments can provide additional benefits in managing COPD. The study will also measure the levels of Astegolimab in the blood and check for any immune responses to the drug.